Lynch syndrome(LS)is a highly penetrant inherited cancer predisposition syndrome,characterized by autosomal dominant inheritance and germline mutations in DNA mismatch repair(MMR)genes,including MLH1,MSH2,MSH6 and PMS...Lynch syndrome(LS)is a highly penetrant inherited cancer predisposition syndrome,characterized by autosomal dominant inheritance and germline mutations in DNA mismatch repair(MMR)genes,including MLH1,MSH2,MSH6 and PMS2.This study aimed to analyze the molecular defects and clinical manifestations of three LS families and propose individual prevention strategies suitable for mutation carriers in different families.The pathogenic gene mutations in each family were identified based on immunohistochemistry results combined with whole-exome sequencing.展开更多
Gene therapy has become the most effective treatment for monogenic diseases.Congenital LEPTIN deficiency is a rare autosomal recessive monogenic obesity syndrome caused by mutations in the Leptin gene.Ob/ob mouse is a...Gene therapy has become the most effective treatment for monogenic diseases.Congenital LEPTIN deficiency is a rare autosomal recessive monogenic obesity syndrome caused by mutations in the Leptin gene.Ob/ob mouse is a monogenic obesity model,which carries a homozygous point mutation of C to T in Exon 2 of the Leptin gene.Here,we attempted to edit the mutated Leptin gene in ob/ob mice preadipocytes and inguinal adipose tissues using CRISPR/Cas9 to correct the C to T mutation and restore the production of LEPTIN protein by adipocytes.The edited preadipocytes exhibit a correction of 5.5%of Leptin alleles and produce normal LEPTIN protein when differentiated into mature adipocytes.The ob/ob mice display correction of 1.67%of Leptin alleles,which is sufficient to restore the production and physiological functions of LEPTIN protein,such as suppressing appetite and alleviating insulin resistance.Our study suggests CRISPR/Cas9-mediated in situ genome editing as a feasible therapeutic strategy for human monogenic diseases,and paves the way for further research on efficient delivery system in potential future clinical application.展开更多
基金This study was supported by Wuhan Municipal Health Commission(No.WX18M02 and No.WX21Q08)。
文摘Lynch syndrome(LS)is a highly penetrant inherited cancer predisposition syndrome,characterized by autosomal dominant inheritance and germline mutations in DNA mismatch repair(MMR)genes,including MLH1,MSH2,MSH6 and PMS2.This study aimed to analyze the molecular defects and clinical manifestations of three LS families and propose individual prevention strategies suitable for mutation carriers in different families.The pathogenic gene mutations in each family were identified based on immunohistochemistry results combined with whole-exome sequencing.
基金supported by grants from the National Natural Science Foundation of China(81573432,81470458 and 81800704)the Ministry of Education of China(NCET-10-0409)。
文摘Gene therapy has become the most effective treatment for monogenic diseases.Congenital LEPTIN deficiency is a rare autosomal recessive monogenic obesity syndrome caused by mutations in the Leptin gene.Ob/ob mouse is a monogenic obesity model,which carries a homozygous point mutation of C to T in Exon 2 of the Leptin gene.Here,we attempted to edit the mutated Leptin gene in ob/ob mice preadipocytes and inguinal adipose tissues using CRISPR/Cas9 to correct the C to T mutation and restore the production of LEPTIN protein by adipocytes.The edited preadipocytes exhibit a correction of 5.5%of Leptin alleles and produce normal LEPTIN protein when differentiated into mature adipocytes.The ob/ob mice display correction of 1.67%of Leptin alleles,which is sufficient to restore the production and physiological functions of LEPTIN protein,such as suppressing appetite and alleviating insulin resistance.Our study suggests CRISPR/Cas9-mediated in situ genome editing as a feasible therapeutic strategy for human monogenic diseases,and paves the way for further research on efficient delivery system in potential future clinical application.
